Decreased secretion of MMP by non-lesional late-stage scleroderma fibroblasts after selection via activation of the apoptotic fas-pathway

Journal of Cellular Physiology

Volumn 226, Issue 7, 2011, Pages 1907-1914

  Chabaud, Stéphane ^a,b   Corriveau, Marie Pier ^a,b   Grodzicky, Tamara ^c,d   Senécal, Jean Luc ^c,d   Chartier, Suzanne ^d,e   Raymond, Yves ^c,d   Moulin, Véronique J ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c NOTRE DAME HOSPITAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; MATRIX METALLOPROTEINASE;

ADULT; APOPTOSIS; ARTICLE; CELL SUBPOPULATION; CONTROLLED STUDY; ENZYME RELEASE; FIBROBLAST; FIBROSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SCLERODERMA; SYSTEMIC SCLEROSIS;

EID: 79955002341     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22520     Document Type: Article

References (38)

1. Ashkenazi A, Dixit VM. 1998. Death receptors: Signaling and modulation. Science (New York, NY) 281:1305-1308.
2. Bhattacharyya S, Chen SJ, Wu M, Warner-Blankenship M, Ning H, Lakos G, Mori Y, Chang E, Nihijima C, Takehara K, Feghali-Bostwick C, Varga J. 2008. Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: Implications for scleroderma. Am J Pathol 173:1085-1099.
3. Bogatkevich GS, Gustilo E, Oates J, Feghali-Bostwick C, Harley R, Silver RM, Ludwicka-Bradley A. 2005. Distinct PKC isoforms mediate cell survival and DNA synthesis inthrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol 288:L190-L201.
4. Bogatkevich GS, Ludwicka-Bradley A, Highland KB, Hant F, Nietert PJ, Singleton CB, Feghali-Bostwick CA, Silver RM. 2007. Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: Possible role in systemic sclerosis. Arthritis Rheum 56:2432-2442.
5. Botstein GR, Sherer GK, Leroy EC. 1982. Fibroblast selection in scleroderma. An alternative model of fibrosis. Arthritis Rheum 25:189-195.
6. Chabaud S, Lambert H, Sasseville AM, Lavoie H, Guilbault C, Massie B, Landry J, Langelier Y. 2003. The R1 subunit of herpes simplex virus ribonucleotide reductase has chaperone-like activity similar to Hsp27. FEBS Lett 545:213-218.
7. Copp J, Wiley S, Ward M, van der Geer P. 2005. Hypertonic shock inhibits growth factor receptor signaling, induces caspase-3 activation, and causes reversible fragmentation of the mitochondrial network. Am J Physiol Cell Physiol 288:C403-C415.
8. Corriveau M, Boufaied I, Lessard J, Chabaud S, Senécal J, Grodzicky T, Chartier S, Raymond Y, Moulin V. 2009. Fibrotic phenotype of Systemic Sclerosis fibroblasts varies with disease duration and severity of skin involvment. J Pathol 217:534-542.
9. Criollo A, Galluzzi L, Maiuri MC, Tasdemir E, Lavandero S, Kroemer G. 2007. Mitochondrial control of cell death induced by hyperosmotic stress. Apoptosis 12:3-18.
10. Derk CT, Jimenez SA. 2003. Systemic sclerosis: Current views of its pathogenesis. Autoimmun Rev 2:181-191.
11. Deveraux QL, Reed JC. 1999. IAP family proteins-Suppressors of apoptosis. Genes Dev 13:239-252.
12. Duncan MR, Perlish JS, Fleischmajer R. 1984. Lymphokine/monokine inhibition of fibroblast proliferation and collagen production: Role in progressive systemic sclerosis (PSS). J Invest Dermatol 83:377-384.
13. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, Tinel A, Deperthes D, Calderara S, Schulthess T, Engel J, Schneider P, Tschopp J. 2003. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 23:1428-1440.
14. Ingegnoli F, Trabattoni D, Saresella M, Fantini F, Clerici M. 2003. Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis. Clin Immunol 108:21-28.
15. Jelaska A, Korn JH. 2000. Role of apoptosis and transforming growth factor b1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 43:2230-2239.
16. Jelaska A, Arakawa M, Broketa G, Korn JH. 1996. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 39:1338-1346.
17. Jun JB, Kuechle M, Harlan JM, Elkon KB. 2003. Fibroblast and endothelial apoptosis in systemic sclerosis. Curr Opin Rheumatol 15:756-760.
18. Jun JB, Kuechle M, Min J, Shim SC, Kim G, Montenegro V, Korn JH, Elkon KB. 2005. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J Invest Dermatol 124:298-303.
19. Kahaleh MB, LeRoy EC. 1986. Effect of scleroderma serum on human fibroblast collagen production: Possible selection through proliferation. J Rheumatol 13:99-102.
20. Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L. 2005. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 64:1233-1235.
21. Kim JY, Kwok SK, Hur KH, Kim HJ, Kim NS, Yoo SA, Kim WU, Cho CS. 2008. Up-regulated macrophage migration inhibitory factor protects apoptosis of dermal fibroblasts in patients with systemic sclerosis. Clin Exp Immunol 152:328-335.
22. Kroemer G, Reed JC. 2000. Mitochondrial control of cell death. Nat Med 6:513-519.
23. Liakouli V, Manetti M, Pacini A, Tolusso B, Fatini C, Toscano A, Cipriani P, Guiducci S, Bazzichi L, Codullo V, Ruocco L, Dell'orso L, Carubbi F, Marrelli A, Abbate R, Bombardieri S, Ferraccioli G, Montecucco C, Valentini G, Matucci-Cerinic M, Ibba-Manneschi L, Giacomelli R. 2009. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis 68:584-590.
24. Michea L, Combs C, Andrews P, Dmitrieva N, Burg MB. 2002. Mitochondrial dysfunction is an early event in high-NaCl-induced apoptosis of mIMCD3 cells. Am J Physiol Renal Physiol 282:F981-F990.
25. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. 2005. Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol 124:886-892.
26. Moulin V, Plamondon M. 2002. Differential expression of collagen integrin receptor on human fetal versus adult skin fibroblasts: Implication in wound contraction during healing. Br J Dermatol 147:886-892.
27. Moulin V, Larochelle S, Langlois C, Thibault I, Lopez-Valle CA, Roy M. 2004. Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors. J Cell Physiol 198:350-358.
28. Nagata S, Golstein P. 1995. The fas death factor. Science (New York, NY) 267:1449-1456.
29. Nietert PJ, Mitchell HC, Bolster MB, Shaftman SR, Tilley BC, Silver RM. 2006. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol 33:263-268.
30. Santiago B, Galindo M, Rivero M, Pablos JL. 2001. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum 44:1667-1676.
31. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME. 1998. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17:1675-1687.
32. Scaffidi C, Schmitz I, Krammer PH, Peter ME. 1999. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 274:1541-1548.
33. Shanahan WR, Jr., Korn JH. 1982. Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity. Arthritis Rheum 25:1391-1395.
34. Sherriff-Tadano R, Ohta A, Morito F, Mitamura M, Haruta Y, Koarada S, Tada Y, Nagasawa K, Ozaki I. 2006. Antifibrotic effects of hepatocyte growth factor on scleroderma fibroblasts and analysis of its mechanism. Mod Rheumatol 16:364-371.
35. Strehlow D, Korn J. 1998. Biology of the scleroderma fibroblast. Curr Opin Rheumatol 10:572-578.
36. Wei Y, Fan T, Yu M. 2008. Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin (Shanghai) 40:278-288.
37. Yamamoto T, Nishioka K. 2004. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 122:44-50.
38. Yamamoto T, Yokozeki H, Nishioka K. 2007. Fas- and FasL-deficient mice are resistant to the induction of bleomycin-induced scleroderma. Arch Dermatol Res 298:465-468.